Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Portfolio Pulse from Benzinga Newsdesk
Entera Bio Ltd. (ENTX) and OPKO Biologics, a subsidiary of OPKO Health, Inc. (OPK), have entered into a Research Collaboration Agreement. OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera's proprietary oral delivery technology.
September 12, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entera Bio has entered into a research collaboration with OPKO Biologics, which could potentially lead to the development of new products.
The collaboration with OPKO Biologics could potentially lead to the development of new products, which could increase Entera Bio's revenue and profitability in the future.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
OPKO Biologics, a subsidiary of OPKO Health, has entered into a research collaboration with Entera Bio. This could potentially expand the application of OPKO's proprietary peptides.
The collaboration with Entera Bio could potentially expand the application of OPKO's proprietary peptides, which could increase OPKO's revenue and profitability in the future.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100